Phase 1 study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma: Expansion cohort analysis

被引：0

作者：

Hamid, Omid ^{[1
]}

Weise, Amy ^{[2
]}

Lewis, Karl D. ^{[3
]}

Kim, Tae Min ^{[4
]}

McKean, Meredith ^{[5
]}

Lakhani, Nehal J. ^{[6
]}

Kaczmar, John ^{[7
]}

Papadopoulos, Kyriakos P. ^{[8
]}

Chen, Shuquan ^{[9
]}

Mani, Jayakumar ^{[9
]}

Gullo, Giuseppe ^{[9
]}

机构：

[1] Cedars Sinai Affiliate, Angeles Clin & Res Inst, Los Angeles, CA USA

[2] Henry Ford Hosp, Detroit, MI USA

[3] Univ Colorado, Denver Canc Ctr, Aurora, CO USA

[4] Seoul Natl Univ Hosp, Seoul, South Korea

[5] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA

[6] START Midwest, Grand Rapids, MI USA

[7] Hollings Canc Ctr, Charleston, SC USA

[8] START San Antonio, San Antonio, TX USA

[9] Regeneron Pharmaceut Inc, Tarrytown, NY USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

43001

引用

页码：AB207 / AB207

页数：1

共 50 条

[21] Prognostic Value of Lymphocyte Activation Gene-3 (LAG-3) Expression in Esophageal Squamous Cell Carcinoma
Zhang, Yu
Liu, Yong-dong
Luo, Yi-ling
Liu, Bin-liu
Huang, Qi-tao
Wang, Fang
Zhong, Qian
JOURNAL OF CANCER, 2018, 9 (22): : 4287 - 4293
[22] A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced ccRCC.
Kim, Miso
McDermott, Raymond S.
Williamson, Stephen K.
Cho, Byoung Chul
Dowlati, Afshin
Lakhani, Nehal J.
Malhotra, Jyoti
Kaczmar, John M.
Papadopoulos, Kyriakos P.
Safran, Howard
Aljumaily, Raid
Mani, Jayakumar
Fang, Fang
Chen, Shuquan
Salvati, Mark
Lowy, Israel
Fury, Matthew G.
Lewis, Karl
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 434 - 434
[23] Biochemical analysis of the regulatory T cell protein lymphocyte activation gene-3 (LAG-3; CD223)
Li, NY
Workman, CJ
Martin, SM
Vignali, DAA
JOURNAL OF IMMUNOLOGY, 2004, 173 (11): : 6806 - 6812
[24] Prognostic significance of lymphocyte activation gene-3 (LAG3 gene) in uveal melanoma patients
Singh, L.
Singh, M. K.
Kumar, N.
Jha, J.
Lomi, N.
Sen, S.
Kashyap, S.
ANNALS OF ONCOLOGY, 2021, 32 : S1463 - S1464
[25] Prognostic impact of lymphocyte-Activation Gene-3 (LAG-3) expression in triple negative breast cancer
Kim, Ji-Yeon
Kim, Jeehyun
Jung, Hae Hyun
Cho, Eun Yoon
Park, Yeon Hee
Ahn, Jin Seok
Kim, Kyoung-Mee
Im, Young-Hyuck
CANCER RESEARCH, 2023, 83 (05)
[26] Role of Lymphocyte Activation Gene-3 (Lag-3) in Conventional and Regulatory T Cell Function in Allogeneic Transplantation
Sega, Emanuela I.
Leveson-Gower, Dennis B.
Florek, Mareike
Schneidawind, Dominik
Luong, Richard H.
Negrin, Robert S.
PLOS ONE, 2014, 9 (01):
[27] Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy
Yu, Xiaojie
Huang, Xiao
Chen, Xiuxiu
Liu, Jianfei
Wu, Chenglin
Pu, Qian
Wang, Yuxiao
Kang, Xiaoqiang
Zhou, Lijun
MABS, 2019, 11 (06) : 1139 - 1148
[28] Phase I study of LBL-007, a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody in patients with advanced solid tumors.
Shi, Yuankai
Luo, Suxia
Zhou, Huan
Zhou, Shengyu
An, Shan
Wang, Zishu
Yang, Sheng
Li, Ning
Li, Xiaoli
Yang, Xinyi
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[29] Soluble pig lymphocyte activation gene-3 (LAG-3; CD223) inhibits human-to-pig xenogeneic mixed lymphocyte reaction
Kim, Seon-Soo
Byun, Hyun-Jung
Kim, Sang-Hoon
Lee, Han-Hyoung
Lee, Suk Jun
Kim, Sang Joon
Park, Chung-Gyu
Chun, Taehoon
BIOTECHNOLOGY LETTERS, 2010, 32 (02) : 203 - 208
[30] Soluble pig lymphocyte activation gene-3 (LAG-3; CD223) inhibits human-to-pig xenogeneic mixed lymphocyte reaction
Seon-Soo Kim
Hyun-Jung Byun
Sang-Hoon Kim
Han-Hyoung Lee
Suk Jun Lee
Sang Joon Kim
Chung-Gyu Park
Taehoon Chun
Biotechnology Letters, 2010, 32 : 203 - 208

← 1 2 3 4 5 →